



## INTERIM REPORT FOR THE PERIOD 28 AUGUST TO 30 SEPTEMBER 2015

Nuevolution AB (publ) (corp.ID 559026-4304) reports its first financial results for the first quarter of 2015/16 for the period ending 30 September, 2015.

As of 30 September 2015, the Company's assets consisted of cash and cash equivalents amounting to SEK 50,000. At the same date, liabilities and shareholders' equity amounted to SEK 50,000, which consisted of share capital. The Company has no credits or bank loans. The company's equity ratio at 30 September 2015 was 100%.

Nuevolution AB (publ) was founded on August 28 by a deposit of share capital amounting to SEK 50,000. No investments in fixed assets were made during the period. The company has been inactive for the quarter that ended 30 September, 2015 and the company had no employees during this period.

During the quarter that ended 30 September, 2015 the company had no revenues, expenses, financial income or expenses, and no tax income or tax expenses.

Total cash flow for the quarter that ended September 30, 2015 amounted to SEK 50,000, which is solely derived from the initial deposit of share capital of SEK 50,000.

### Significant events after the end of the period

During the second quarter that ends December 31, Nuevolution AB (publ) intends to incorporate the business of Nuevolution A/S through a non-cash issue. Nuevolution AB (publ) will therefore be the sole owner of Nuevolution A/S.

Nuevolution AB (publ) is considering an initial public offering on Nasdaq First North Premier, and look forward to welcoming new shareholders to the company. The company has developed a patented "state-of-the-art" platform for drug development based on small molecules, Chemetics, a happy "marriage" between chemistry and technology. This platform has attracted large pharmaceutical partners, such as Novartis, Merck (MSD) and Janssen Biotech (a subsidiary of Johnson & Johnson). Chemetics supports the company's "multiple shots at goal" – business strategy, because it enables lower costs, faster development, higher hit rate and cash flow. The company focuses on the areas of oncology and inflammation, diseases of high unmet medical need, which permits early out-licensing, but still generates attractive milestone payments and royalties.

### Significant risks and uncertainties

The company's operations and results are affected by a number of external and internal factors. The company's management and Board of Directors constantly monitor the anticipated risks and assess how these can be addressed.

These risks include risks and uncertainties relating to preclinical and clinical development of drug candidates, the reliance of sub-supplier such as CROs and other third parties, the company's ability to protect and defend intellectual property rights, competing new technologies, reliance on key personnel, future needs of capital, pricing, reimbursement and co-funding of medicines, as well as access to medicine.





This interim report has been prepared in accordance with BFNAR 2007:1, "Frivillig delårsrapportering". The Company applies the Swedish "Årsredovisningslagen" and the Swedish BFN's supplementary regulations BFNAR 2012: 1 "Årsredovisning och Koncernredovisning (K3).

Stockholm, 11 November 2015

Viktor Drvota  
*Board member*

### **Future reporting dates**

Report on the second quarter of 2015/16: 4 February, 2016

Report on the third quarter of 2015/16: 3 May, 2016

Report on the fourth quarter of 2015/16: 6 September, 2016

### **More information**

Alex Haahr Gouliaev

Tel.: +45 3913 0902, mobile: +45 2725 1402, email: [ahg@nuevoution.com](mailto:ahg@nuevoution.com)





Income Statement	28 August - 30 September, 2015
<i>SEK'000</i>	
Net Sales	0
Operating profit/loss	0
Profit/loss before tax	0
Profit/loss for the period	0

Balance Sheet	30 September, 2015
<i>SEK'000</i>	
<i>Assets</i>	
Fixed Assets	0
Current Assets	0
Cash and Cash Equivalents	50
<b>Total Assets</b>	<b>50</b>
<i>Liabilities and Equity</i>	
Equity Liabilities	50
	0
<b>Total equity and liabilities</b>	<b>50</b>

Cash flow statement	28 August - 30 September 2015
<i>SEK'000</i>	
Cash flow from operating activities	0
Cash flow from investing activities	0
Cash flow from financing activities	50
<b>Net cash flow</b>	<b>50</b>
Cash and cash equivalents beginning of period	0
<b>Net cash flow</b>	<b>50</b>
<b>Cash and cash equivalents end of period</b>	<b>50</b>

